(Wilmington, N.C.) PPD, Inc. (Nasdaq: PPDI) announced it has expanded its cGMP laboratory testing services into Wayne, Pa., to meet growing client demand for these services from pharmaceutical and biotechnology companies located in the northeastern United States. (more…)

(Wilmington, N.C.) PPD, Inc. (Nasdaq: PPDI) reported its financial and operating results for the second quarter ended June 30, 2010. (more…)

(Durham, N.C.) Health Decisions (www.HealthDec.com), a full-service contract research organization (CRO) specializing in high-efficiency adaptive solutions, has appointed Bryan Minihan as Chief Technology Officer. Minihan will strengthen Health Decisions’ proprietary HD360° technology platform—the fully integrated CTMS, CDMS and web portal that powers the company’s Agile Clinical Development methodology. By expanding the capabilities of HD360°, Health Decisions will provide its sponsors with extended data capture options; a collaborative and secure web-based platform to house near real-time data and metrics; and the ability to acquire timely, actionable insight into operational status. (more…)

(Research Triangle Park, N.C.) Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide, today announced that it has been named the 2010 Asia Pacific Contract Research Organization (CRO) Company of the Year by Frost & Sullivan. This is the third time in the last five years that Quintiles Asia-Pacific has been honored by the leading growth partnership firm for its performance in the region. Presented at the recent 2010 Frost & Sullivan Asia Pacific Best Practices Awards banquet in Singapore, the award honors the company that exhibited excellence in growth strategy and implementation, innovation as well as overall customer and market leadership. (more…)

(Research Triangle Park, N.C.) Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide, today announced a strategic alliance agreement with the University Malaya Medical Centre (UMMC) as part of its unique Prime Site program - an initiative focused on accelerating the development of new and more effective medicines. The UMMC is the first Prime Site in Asia for Quintiles, adding to its existing four other sites located in the United States, Europe and Africa. (more…)

(Research Triangle Park, N.C.) Quintiles most consistently meets or exceeds customer expectations and is the No. 1 preferred provider and perceived industry leader across all phases of clinical research, according to 150 biopharmaceutical industry decision-makers surveyed by the independent firm Industry Standard Research (ISR). (more…)

(Durham, N.C.) Full-service contract research organization (CRO) Health Decisions (www.HealthDec.com) will launch the “Demand More” campaign at the 46th DIA Annual Meeting, June 13 – 17 in Washington, D.C. (Booth #929). Attendees will be able to experience demonstrations of trial management techniques that meet or exceed enrollment goals for 83 percent of studies. (more…)

(Wilmington, N.C.) PPD, Inc. (Nasdaq: PPDI) announced today its board of directors has set the shareholder of record and distribution dates in connection with the spin-off of its wholly-owned subsidiary, Furiex Pharmaceuticals, Inc. Shareholders of record of PPD on June 1, 2010, will receive on June 14, 2010, a pro-rata dividend of one share of Furiex Pharmaceuticals common stock for every 12 shares of PPD common stock. Any fractional shares will be paid in cash. PPD common stock will continue to trade on Nasdaq under the ticker symbol “PPDI.” Shares of Furiex Pharmaceuticals will be listed on Nasdaq under the ticker symbol “FURX.” It is anticipated that these shares will begin trading “when issued” on Nasdaq on or prior to the record date, with any trades settling within three days after the distribution date. (more…)

(Wilmington, N.C.) PPD, Inc. (Nasdaq: PPDI) today announced that its board of directors declared a cash dividend for the second quarter of 2010 under its annual cash dividend policy. The quarterly cash dividend will equal $0.15 per share. The record date for the second quarter dividend is June 15, 2010, and the payment date is June 29, 2010. The annual cash dividend policy and the payment of future quarterly cash dividends under that policy are subject to the continuing determination by the board of directors that the policy remains in the best interests of the company’s shareholders and in compliance with applicable laws and agreements. (more…)

(Wilmington, N.C.) PPD, Inc. (Nasdaq: PPDI) today announced its contract research facility in Athlone, Ireland, has been awarded manufacturer licenses by the Irish Medicines Board (IMB). The licenses support investigational medicinal products and marketed products and provide laboratory certifications for quality control of medicinal products. (more…)

(Wilmington, N.C.) PPD, Inc. (Nasdaq: PPDI) today announced it has opened a vaccine clinical research center in Taizhou, China, further strengthening its clinical research and development services in one of the country’s major regions for conducting vaccine studies. Through the center, PPD will provide clinical monitoring services to global and local biopharmaceutical companies seeking to develop vaccines in China. (more…)

(Cary, N.C.) Industry Standard Research (ISR Reports) today announced the launch of the 2010 Edition of the CRO Quality Benchmarking Report. 150 pharmaceutical and biotechnology professionals provided their experiences with dozens of small, mid-size and large CROs in this “Consumer Reports”-style analysis of the industry. In total, data were collected on over 740 Sponsor / CRO interactions. (more…)